Genmab — Juli 2022
-
Ja..Det var tydeligt at se.
-
Selv Oslo reagerede negativt.
-
-
Der var vist en efterregulering på europæisk PMI kl. 10. Den burde ikke kunne rykke markederne i noget særligt omfang.
-
Reguleringen var endda til den positive side.
-
Aktier/middag: C25 tynges af makrousikkerhed - SAS i tocifret fald https://www.proinvestor.com/investornyt/845961/aktier-middag-c25-tynges-af-makrousikkerhed-sas-i-tocifret-fald
-
Det ender med, at Helge må invitere på romkugler og Bjørnebryg i baghaven....
-
-
-
Data from Johnson & Johnson's Phase II LYNX study, which due to readout late this year or in early 2023, could provide some answers. This trial is evaluating Darzalex in combination with Kyprolis (carfilzomib) and dexamethasone (Kd), versus Kd alone, in approximately 230 patients that have received one to three prior lines of therapy, one of which contained Darzalex.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind